Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer IngelheimNov 29, 2022
Ribon Therapeutics Announces Late-Breaking Presentation of Preclinical Data on RBN-3143 at the European Respiratory Society International Congress 2022Sep 6, 2022
Ribon Therapeutics Announces Presentations at the American Association for Cancer Research 2022 Annual MeetingApr 11, 2022
Ribon Therapeutics Announces Initiation of Phase 1b/2 Study of RBN-2397 in Combination with Pembrolizumab in Patients with Squamous Cell Carcinoma of the LungMar 29, 2022